Abstract
Objectives The aim of this study is to measure α-defensin-1 expression in the peripheral blood of patients with Behçet's disease (BD) and healthy control (HC) and to assess the association between α-defensin-1 expression and clinical features of BD. Methods Our patients fulfilled the diagnostic criteria of the international BD study group. ELISA and real-time PCR were performed to measure α-defensin-1 protein level in the sera and α-defensin-1 mRNA level in peripheral blood mononuclear cells (PBMC), respectively. Results The α-defensin-1 mRNA expression was significantly higher in BD patients ( n = 59) than HC ( n = 34) (0.49 ± 0.10 vs. 0.19 ± 0.45, P = 0.03). The level of α-defensin-1 mRNA and protein was significantly higher in active patients than inactive patients ( n = 15, 0.91 ± 0.28 vs. n = 44, 0.35 ± 0.09, P < 0.001 and n = 21, 7.50 ± 2.14 ng/ml vs. n = 50, 3.32 ± 0.96 ng/ml, P = 0.001, respectively). The level of α-defensin-1 mRNA was significant higher in patients with arthritis ( n = 20) than those without arthritis ( n = 39). Conclusion α-defensin-1 mRNA and protein levels are significantly increased in BD patients, especially in active BD patients. Furthermore, α-defensin-1 mRNA is over-expressed in the PBMC of BD patients with arthritis. The present study suggests that α-defensin-1 may be involved in the pathogenesis of BD and can be used as valuable biologic marker for estimation of disease activity in BD.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call